Incyte (INCY) Depreciation & Amortization (CF) (2010 - 2026)
Incyte (INCY) posted Depreciation & Amortization (CF) of $23.8 million for Q1 2026, down 0.75% on a QoQ basis from $24.0 million in Q4 2025, and up 6.44% year-over-year from $22.4 million in Q1 2025.
Incyte (INCY) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Incyte's Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $23.8 million for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 6.44% year-over-year to $23.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $94.7 million (up 5.65% YoY) and the FY2025 annual result came in at $93.3 million, up 4.52% from the prior year.
- Depreciation & Amortization (CF) was $23.8 million for Q1 2026 at Incyte, down from $24.0 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $24.0 million in Q3 2025 and bottomed at $16.4 million in Q1 2022.
- A 5-year average of $21.0 million and a median of $21.9 million in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) increased 28.15% — and 2025, when it increased 1.89%.
- Incyte's Depreciation & Amortization (CF) stood at $18.2 million in 2022, then climbed by 19.45% to $21.8 million in 2023, then advanced by 4.46% to $22.7 million in 2024, then rose by 5.49% to $24.0 million in 2025, then decreased by 0.75% to $23.8 million in 2026.
- Business Quant data shows INCY's Depreciation & Amortization (CF) at $23.8 million in Q1 2026, $24.0 million in Q4 2025, and $24.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Incyte | 23.33 Bn | 19.32 Bn | 1.17 Bn | 23.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.80 Mn |
| Mar 31, 2026 | 23.80 Mn |
| Dec 31, 2025 | 23.98 Mn |
| Dec 31, 2025 | 23.98 Mn |
| Sep 30, 2025 | 24.02 Mn |
| Sep 30, 2025 | 24.02 Mn |
| Jun 30, 2025 | 22.92 Mn |
| Jun 30, 2025 | 22.92 Mn |
| Mar 31, 2025 | 22.36 Mn |
| Mar 31, 2025 | 22.36 Mn |
| Dec 31, 2024 | 22.73 Mn |
| Dec 31, 2024 | 22.73 Mn |
| Sep 30, 2024 | 22.52 Mn |
| Sep 30, 2024 | 22.52 Mn |
| Jun 30, 2024 | 22.05 Mn |
| Jun 30, 2024 | 22.05 Mn |
| Mar 31, 2024 | 21.95 Mn |
| Mar 31, 2024 | 21.95 Mn |
| Dec 31, 2023 | 21.76 Mn |
| Dec 31, 2023 | 21.76 Mn |